Table 7. Pharmacokinetic parameters of VST in different formulations in rats.
| Parameters | Diovan® powder | SuSMEDDS | Optimized S-SuSMEDDS granules |
|---|---|---|---|
| AUC0-12 (ng·h/mL) | 5561.5 ± 2883.4 | 11463.3 ± 4523.1* | 12350.5 ± 3774.5* |
| Cmax (ng/mL) | 849.3 ± 476.5 | 3120.6 ± 2367.7* | 3337.9 ± 1396.6* |
| Tmax (h) | 0.93 ± 0.60 | 1.17 ± 0.66 | 0.63 ± 0.51 |
| RBA (%) | |||
| vs. Diovan® | - | 206.1 | 222.1 |
| vs. SuSMEDDS | - | - | 107.7 |
*Significantly different at p < 0.05 versus Diovan® powder. Values are presented as the mean ± SD (n = 6-7).
Abbreviations:VST, valsartan; S-SuSMEDDS, solidified supersaturable self-microemulsifying drug delivery system; AUC, area under the curve; Cmax, peak plasma concentration; Tmax, time to peak plasma; RBA, relative bioavailability; SuSMEDDS, supersaturable self-microemulsifying drug delivery system.